Peptide receptor radiotherapy: A new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group

British Journal of Cancer

Volumn 88, Issue 5, 2003, Pages 645-647

  De Pas, T ^a   Bodei, L ^a   Pelosi, G ^a   De Braud, F ^a   Villa, G ^a   Capanna, R ^b   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CTO   (Italy)

Author keywords

Desmoid tumour; External beam radiation therapy; Fibromatosis; Receptor radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE Y 90; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER THERAPY; CASE REPORT; CLINICAL RESEARCH; FEMALE; FIBROMATOSIS; HUMAN; MALE; PRIORITY JOURNAL; RADIOSENSITIVITY;

ADULT; CASE REPORT; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMAN; MALE; OCTREOTIDE; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RECEPTORS, PEPTIDE; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 0242600539     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600823     Document Type: Article

References (12)

1. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med. Published online: 16 November 2002
2. 3-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 32: 141-147
3. Cremonesi M, Ferrari M, Zoboli S, Chlnol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G (1999) Biokinetics and dosimetry in patients administered with (111)InDOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 26: 877-886
4. Greenberg HM, Goebel R, Weichselbaum RR, Greenberger JS, Chaffey JT, Cassady JR (1981) Radiation therapy in the treatment of aggressive fibromatosis. Int J Radiat Oncol 7: 305-310
5. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur 7: 1974-1981
6. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731
7. Kwekkeboom D, Krenning EP, de Jong M (2000) Peptide receptor imaging and therapy. J Nucl Med 41: 1704-1713
8. Mannant PR, Beau P, De Ledinghen V, Barrioz T, Genestin E (1995) Partial regression of a desmoid tumor after prolonged treatment with lanreotide. Gastroenterol Clin Biol 19: 1072-1073
9. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
10. Nuyttens JJ, Rust PF, Thomas Jr CR, Turrisi III AT (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88: 1517-1523
11. 3-octreotide. Eur J Nucl Med 28: 426-434
12. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol 12: 941-945